JAMA Network Home
Sign In
Original Investigation

Safety and Preliminary Efficacy of Dengue Monoclonal Antibody in Adult Patients

JAMA Network Open 10.1001/jamanetworkopen.2026.29979

August 25, 2026 at 11:00 AM EDT

Read the full article

In this randomized clinical trial, Dengue-mAb was safe and well tolerated. Dengue-mAb rapidly reduced dengue viremia and fever at doses of 5 mg/kg and 7 mg/kg, making this the first therapeutic against wild-type dengue virus to show preliminary efficacy in humans.

Corresponding Author: Prasad S. Kulkarni, MD, Serum Institute of India, Pune 411028, India (drpsk@seruminstitute.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.29979?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082526

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks